Aarti Pharmalabs Ltd (AARTIPHARM) — Announcement | 31 August 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Senior General Manager G.M. Naidu resigns effective August 31, 2026
💡 Investor Takeaway
This leadership change may affect operational continuity but does not signal financial distress.

Aarti Pharmalabs announced the resignation of Senior General Manager G.M. Naidu effective August 31, 2026, citing personal commitments, with his last day of service confirmed in a June 10 email. The filing complies with SEBI Listing Regulation 30 and includes his resignation details in Annexure A.

📄 View Original Announcement (PDF)

About Aarti Pharmalabs Ltd (AARTIPHARM)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹7,657.91 Cr P/E: 35.9 ROE: 10.7% ROCE: 14.1% Div Yield: 0.41%

View full AARTIPHARM stock details →

📡 Get AI alerts when AARTIPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AARTIPHARM — Free

📊 More AARTIPHARM filings

See all AARTIPHARM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AARTIPHARM files new disclosures

Track AARTIPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AARTIPHARM — Free

Free account · 2 AI queries/day